Is Hydrocortisone safe in pregnancy?
Reading File
Finding Sources
Searching PubMed
hydrocortisone corticosteroids pregnancy safety
Searching the Web
hydrocortisone safety in pregnancy FDA category evidence 2025
Reading File
Reading File
Searching PubMed
topical corticosteroids pregnancy fetal outcome
I now have comprehensive information to give a thorough, well-sourced answer.
Hydrocortisone Safety in Pregnancy
The answer depends significantly on route of administration (topical vs. systemic), dose, and gestational timing. Here is a breakdown:
Systemic Hydrocortisone (Oral / IV / IM)
Generally safe when used at physiologic/replacement doses for conditions like adrenal insufficiency or congenital adrenal hyperplasia (CAH).
Key points from authoritative sources:
-
Women with adrenal insufficiency can undergo healthy pregnancy, labor, and delivery on hydrocortisone replacement. The standard oral dose of 15-25 mg/day may need to be increased by ~50% in the third trimester due to higher physiologic cortisol demand. - Harrison's Principles of Internal Medicine 22E (2025)
-
During labor and delivery, a bolus of 100 mg IV hydrocortisone is recommended, followed by infusion, to cover the physiologic stress response. - Tintinalli's Emergency Medicine
-
Women with CAH who are on dexamethasone should be switched to hydrocortisone during pregnancy, specifically to avoid fetal exposure - dexamethasone crosses the placenta more readily than hydrocortisone. - Creasy & Resnik's Maternal-Fetal Medicine
-
Excess glucocorticoid must be avoided: supraphysiologic doses can cause fetal adrenal suppression, leading to transient adrenocortical insufficiency in the neonate. - Creasy & Resnik's Maternal-Fetal Medicine
Placental metabolism is protective: The enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) converts active cortisol (hydrocortisone) to inactive cortisone at the placental level, providing a barrier that protects the fetus. However, this barrier is not absolute - roughly 15% of maternal hydrocortisone can cross to the fetal compartment without being metabolized. (NIH/PMC evidence)
Topical Hydrocortisone (0.5%-1% cream/ointment)
Low-potency topical hydrocortisone is generally considered acceptable throughout pregnancy.
-
OTC hydrocortisone 0.5%-1% is first-line treatment for atopic dermatitis and eczema-associated pruritus in pregnancy, with no evidence of teratogenicity at these concentrations. - American Family Physician, 2023
-
A large cohort study of over 35,000 pregnancies found no association between mild topical steroid use and adverse pregnancy outcomes (birth defects, preterm delivery, low birth weight).
-
High-potency topical steroids applied in large amounts carry a probable association with low birth weight and hypothalamic-pituitary-adrenal (HPA) axis suppression in the neonate. These should be avoided.
-
Systemic absorption from topical hydrocortisone is minimal when applied to intact skin in small areas, making it far safer than systemic formulations.
Intranasal / Inhaled Hydrocortisone
Systemic absorption is very low. When clinically indicated (e.g., asthma, severe allergic rhinitis), the benefit of disease control generally outweighs the minimal systemic risk.
Summary Table
| Form | Safety in Pregnancy | Notes |
|---|---|---|
| Topical 0.5-1% (OTC) | Acceptable throughout | Preferred first-line for skin conditions |
| Topical high-potency | Avoid / limit | Risk of low birth weight, HPA suppression |
| Systemic (physiologic dose) | Safe when indicated | Increase dose 50% in third trimester; preferred over dexamethasone for adrenal conditions |
| Systemic (supraphysiologic) | Avoid unless essential | Risk of fetal/neonatal adrenal suppression |
| IV 100 mg bolus at labor | Recommended in adrenal insufficiency | Standard stress-dose protocol |
FDA Classification
Hydrocortisone is FDA Pregnancy Category C - animal studies show adverse fetal effects, no adequate human controlled trials, but potential benefits may warrant use despite risks. The current labeling typically states "use only if benefit justifies the potential risk to the fetus."
Bottom line: Low-dose topical hydrocortisone (0.5-1%) is safe for short-term use in pregnancy. Systemic hydrocortisone at physiologic replacement doses is appropriate and preferred over dexamethasone/prednisone for conditions like adrenal insufficiency and CAH. The placenta metabolizes most maternal hydrocortisone, providing fetal protection - but supraphysiologic doses should be avoided to prevent neonatal adrenal suppression. Always weigh clinical need against risk, and consult your healthcare provider before use.
This is a shared conversation. Sign in to Orris to start your own chat.